ST
XERS icon

Sphinx Trading’s Xeris Biopharma Holdings XERS Stock Holding History

Sphinx Trading’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4K Buy
+1,404
New +$3.03K ﹤0.01% 138

Other funds holding XERS

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sphinx Trading's XERS Position: Q4 2021 in Review

Sphinx Trading opened a new position in Xeris Biopharma Holdings (XERS) in Q4 2021: 1,404 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #138 among its holdings.

92 funds tracked by Wall St. Rank hold XERS as of Q4 2021.

  • Sphinx Trading held 1,404 shares of Xeris Biopharma Holdings worth $4K as of Q4 2021.
  • Xeris Biopharma Holdings was a new Sphinx Trading position in Q4 2021.
  • Xeris Biopharma Holdings made up ﹤0.01% of Sphinx Trading's portfolio in Q4 2021, its #138 holding.
  • 92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2021.

Based on Sphinx Trading's 13F filing for Q4 2021, filed 31 Jan 2022.